Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Novo Nordisk ( (NVO) ) has provided an update.
On February 4, 2025, Novo Nordisk announced the conclusion of a share repurchase program that started on November 11, 2024, as part of a broader plan to buy back shares worth up to DKK 20 billion over a year beginning February 6, 2024. During this phase, the company repurchased B shares worth approximately DKK 3.1 billion. As of the announcement, Novo Nordisk had acquired nearly 24.8 million B shares with a transaction value close to DKK 20 billion since February 6, 2024, enhancing its financial strategy and potentially influencing its market positioning.
More about Novo Nordisk
Novo Nordisk is a prominent global healthcare enterprise established in 1923 and headquartered in Denmark. The company is devoted to combating severe chronic diseases, with a strong focus on diabetes. It is known for its scientific innovations, expanding access to medications, and efforts to prevent and cure diseases. Novo Nordisk employs approximately 72,000 individuals across 80 countries and markets its products in nearly 170 countries. Its B shares are traded on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange.
YTD Price Performance: -3.51%
Average Trading Volume: 7,941,437
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $369.5B
See more insights into NVO stock on TipRanks’ Stock Analysis page.